Exelixis Inc at Guggenheim Healthy Altitudes Summit Transcript
Good morning. So the next company here is Exelixis. I'm pleased to welcome Andrew Peters, SVP of Strategy. Peters, welcome, and thanks for joining us.
Yes, thanks for having me.
Questions & Answers
So CABOMETYX has obviously been a huge commercial success for Exelixis in -- over the last year, a few years. At this point, how should we think about growth drivers as we head into 2023?
Yes. So I guess just everyone, thanks for having me here. This is a great event. As a reminder, I'll be making some forward-looking statements today. So please see relevant SEC filings for appropriate disclosures.
So yes, Cabo, obviously, great product. One of the things that we talk about a lot internally is really what drives Cabo is a great team, great data. And we can point to something like the 44-month update at the recent ASCO GU
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
